Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow
Vertex Pharma has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year.
Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable a
Three of the four UK nations have agreed a long-term deal with Vertex Pharma for reimbursement of its cystic fibrosis therapies, ensuring permanent access to the drugs for eligible patients
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year